Abstract
BACKGROUND.
Significant controversy surrounds the use of remission induction chemotherapy (IC) in older adults with acute myeloid leukemia (AML). Earlier clinical trials have yielded conflicting results and possibly a minor survival benefit, often offset by a longer hospitalization time.
METHODS.
To evaluate the role of IC in patients with AML, a case control study of patients 60 years or older treated at the Cleveland Clinic Taussig Cancer Center between 1997 and 2005 was conducted. Fortyβfour patients who did not receive IC were matched by a propensity analysis to 138 patients who received an anthracyclineβbased regimen.
RESULTS.
The unadjusted median survival of patients who did not receive IC was 53 days, compared with 197 days (P < .001) for those who did. After further adjusting for age, gender, race, leukocyte count at presentation, AML cytogenetics, history of prior hematologic disorder, and assessing for comorbidities, not receiving IC was still associated with worse survival (hazards ratio of 1.88; 95% confidence interval, 1.15β3.05 [P = .01]). Additional predictors of poor outcomes in older adults with AML included higher leukocyte count at presentation, poorβrisk cytogenetics, and AfricanβAmerican race (compared with Caucasians).
CONCLUSIONS.
The study suggests improved outcomes in older adults with AML who undergo remission induction therapy. Cancer 2007. Β© 2007 American Cancer Society.